Coronavirus Notebook: Valneva Vaccine To Begin EU Rolling Review, Synairgen Reports Progress With Inhaled IFN-Beta
The European Parliament is pushing for more of a say in how Europe’s new emergency response authority, HERA, deals with R&D and procurement of vaccines and therapies in times of health crises. NRx Therapeutics says it will continue to seek US approval of aviptadil for COVID-19.
You may also be interested in...
The European Commission has dismissed concerns about the operation of its new emergency response body, saying it will ensure the EU is well prepared for tackling future pandemics and other threats. HERA will complement, not duplicate, work conducted by existing agencies such as the European Medicines Agency, delegates heard at this week’s European Health Forum Gastein virtual conference.
Efforts to overhaul the EU pharmaceutical legislation have been given added impetus after the European Parliament called for action to boost innovation and medicines access, shore up manufacturing and supply chains, and examine the link between R&D spending and drug prices.
The EMA is going all out to maximize coverage of the EU population with both vaccines and treatments for COVID-19.